Literature DB >> 17072121

Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media.

Robert Cohen1, Corinne Levy, France de La Rocque, Nathalie Gelbert, Alain Wollner, Bernard Fritzell, Eric Bonnet, Robert Tetelboum, Emmanuelle Varon.   

Abstract

BACKGROUND: Penicillin resistance among pneumococci has increased in the past 15 years. The implementation of widespread vaccination with the heptavalent pneumococcal conjugate vaccine (PCV7) and the reduction of inappropriate antibiotic use could help reduce antibiotic resistance.
METHODS: Between September 2001 and June 2004, 89 pediatricians distributed throughout France took part in this prospective study. We obtained 1906 nasopharyngeal swabs for culture from children aged 6 to 24 months with acute otitis media (AOM). At the same time as PCV7 was introduced into the routine immunization schedule, a plan to promote judicious antibiotic use was established. We recorded the frequency of antibiotic use, as well as the dates of immunization with PCV7.
RESULTS: The proportion of PCV7-vaccinated children (> or =1 dose) increased from 8.2% (year 1) to 61.4% (year 3). The proportion of children who received antibiotics within 3 months before enrollment decreased from 51.8% in year 1 to 40.9% in year 3 (P < 0.001). Overall pneumococcal carriage and carriage of PCV7 serotypes decreased during the 3-year period by 16% (P < 0.001) and 35% (P < 0.001), respectively. Rates of highly penicillin resistant strains (PRP) decreased yearly: 15.4%, 10.6%, 6.7% (P < 0.001), respectively. Risks for PRP carriage were 4.2% for immunized children who had not received antibiotics, 8.6% for those vaccinated who also had received antibiotics, 10.3% for unimmunized children who had not received antibiotics, and 16.2% for unimmunized children who had received antibiotics (P < 0.001).
CONCLUSION: Implementation of PCV7, combined with a reduction in antibiotic use, in a country with a high prevalence of antibiotic-resistant pneumococci appears to have a strong impact on the carriage of penicillin nonsusceptible pneumococci in children with AOM.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17072121     DOI: 10.1097/01.inf.0000243163.85163.a8

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  33 in total

Review 1.  Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [Prevenar 13(®)]: profile report.

Authors:  Sean T Duggan
Journal:  Paediatr Drugs       Date:  2012-02-01       Impact factor: 3.022

2.  Pneumococcal nasopharyngeal carriage following reduced doses of a 7-valent pneumococcal conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine booster.

Authors:  F M Russell; J R Carapetis; C Satzke; L Tikoduadua; L Waqatakirewa; R Chandra; A Seduadua; S Oftadeh; Y B Cheung; G L Gilbert; E K Mulholland
Journal:  Clin Vaccine Immunol       Date:  2010-10-13

3.  Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity.

Authors:  Martin C J Maiden; Ana Belén Ibarz-Pavón; Rachel Urwin; Stephen J Gray; Nicholas J Andrews; Stuart C Clarke; A Mark Walker; Meirion R Evans; J Simon Kroll; Keith R Neal; Dlawer A A Ala'aldeen; Derrick W Crook; Kathryn Cann; Sarah Harrison; Richard Cunningham; David Baxter; Edward Kaczmarski; Jenny Maclennan; J Claire Cameron; James M Stuart
Journal:  J Infect Dis       Date:  2008-03-01       Impact factor: 5.226

4.  Impact of a pneumococcal conjugate vaccination program on carriage among children in Norway.

Authors:  Didrik F Vestrheim; E Arne Høiby; Ingeborg S Aaberge; Dominique A Caugant
Journal:  Clin Vaccine Immunol       Date:  2010-01-27

Review 5.  Pneumonia research to reduce childhood mortality in the developing world.

Authors:  J Anthony G Scott; W Abdullah Brooks; J S Malik Peiris; Douglas Holtzman; E Kim Mulholland
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

Review 6.  The multifaceted impact of pneumococcal conjugate vaccine implementation in children in France between 2001 to 2014.

Authors:  Robert Cohen; Sandra Biscardi; Corinne Levy
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

7.  Decrease in antibiotic use, an added benefit of PCVs.

Authors:  Carlos G Grijalva
Journal:  Lancet Infect Dis       Date:  2013-11-26       Impact factor: 25.071

Review 8.  Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?

Authors:  William P Hausdorff; Bernard Hoet; Lode Schuerman
Journal:  BMC Pediatr       Date:  2010-02-02       Impact factor: 2.125

9.  Risk factors for nasopharyngeal carriage of drug-resistant Streptococcus pneumoniae: data from a nation-wide surveillance study in Greece.

Authors:  Ioannis Katsarolis; Garyphallia Poulakou; Antonios Analitis; Irini Matthaiopoulou; Emmanuel Roilides; Charalampos Antachopoulos; Dimitrios A Kafetzis; Georgios L Daikos; Regina Vorou; Christina Koubaniou; Ioannis Pneumatikos; Georgios Samonis; Vasiliki Syriopoulou; Helen Giamarellou; Kyriaki Kanellakopoulou
Journal:  BMC Infect Dis       Date:  2009-07-29       Impact factor: 3.090

10.  Streptococcus pneumoniae serotype 3 among Costa Rican children with otitis media: clinical, epidemiological characteristics and antimicrobial resistance patterns.

Authors:  Arturo Abdelnour; Carolina Soley; Silvia Guevara; Nurith Porat; Ron Dagan; Adriano Arguedas
Journal:  BMC Pediatr       Date:  2009-08-14       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.